首页> 美国卫生研究院文献>other >A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models
【2h】

A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models

机译:TRPC5离子通道的小分子抑制剂可抑制动物模型中的进行性肾脏疾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Progressive kidney diseases are often associated with scarring of the kidney’s filtration unit, a condition called focal segmental glomerulosclerosis (FSGS). This scarring is due to loss of podocytes, cells critical for glomerular filtration, and leads to proteinuria and kidney failure. Inherited forms of FSGS are caused by Rac1-activating mutations, and Rac1 induces TRPC5 ion channel activity and cytoskeletal remodeling in podocytes. Whether TRPC5 activity mediates FSGS onset and progression is unknown. We identified a small molecule, AC1903, that specifically blocks TRPC5 channel activity in glomeruli of proteinuric rats. Chronic administration of AC1903 suppressed severe proteinuria and prevented podocyte loss in a transgenic rat model of FSGS. AC1903 also provided therapeutic benefit in a rat model of hypertensive proteinuric kidney disease. These data indicate that TRPC5 activity drives disease and that TRPC5 inhibitors may be valuable for the treatment of progressive kidney diseases.
机译:进行性肾脏疾病通常与肾脏滤过单元的瘢痕形成有关,这种疾病称为局灶节段性肾小球硬化症(FSGS)。这种瘢痕形成是由于足细胞的丢失,对肾小球滤过至关重要的细胞,并导致蛋白尿和肾衰竭。 FSGS的遗传形式是由Rac1激活突变引起的,Rac1诱导足细胞中的TRPC5离子通道活性和细胞骨架重塑。未知TRPC5活性是否介导FSGS的发作和进展。我们鉴定出一个小分子AC1903,该蛋白专门阻断蛋白尿大鼠肾小球中TRPC5通道的活性。在FSGS转基因大鼠模型中,长期服用AC1903可抑制严重的蛋白尿并防止足细胞丢失。 AC1903在高血压蛋白尿肾病的大鼠模型中也提供了治疗益处。这些数据表明,TRPC5活性驱动疾病,并且TRPC5抑制剂对于进行性肾脏疾病的治疗可能有价值。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号